Condition
Rare Cancers
Total Trials
4
Recruiting
3
Active
4
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 4 (1)
Trial Status
Recruiting3
Active Not Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT03340506Phase 4Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT01505400Active Not Recruiting
Integrated Molecular Profiling in Advanced Cancers Trial
NCT05852522RecruitingPrimary
Molecularly Aided Stratification for Tumor Eradication Research
NCT04504604Not ApplicableRecruitingPrimary
TCF-001 TRACK (Target Rare Cancer Knowledge) Study
Showing all 4 trials